Join to View Full Profile
1364 Clifton Rd NEAtlanta, GA 30322
Phone+1 404-778-1900
Fax+1 617-632-2165
Dr. Berchuck is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jacob Berchuck is an oncologist based in Atlanta, GA, specializing in prostate, kidney, bladder, and testicular cancers. He completed his residency in Internal Medicine at the University of California, San Francisco, and his fellowship in Hematology and Medical Oncology at institutions including Mass General Brigham and Dana-Farber Cancer Institute. He serves as an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Emory University School of Medicine, and as a Medical Oncologist at Winship Cancer Institute of Emory University since 2024. Previously, he worked as a physician at Dana-Farber Cancer Institute and Brigham and Women's Hospital, and as an Assistant Professor at Harvard Medical School. His publications cover topics such as cancer treatment strategies and biomarker-driven approaches.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2017 - 2020
University of California (San Francisco)Residency, Internal Medicine, 2013 - 2016
Duke University School of MedicineClass of 2013
Certifications & Licensure
GA State Medical License 2024 - 2027
MA State Medical License 2017 - 2026
CA State Medical License 2014 - 2018
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177-PSMA-617.Margo B Gerke, Angelo Marra, Michelle Jayaraj, Ahmet Yildrim, Akshay Bedmutha
The Oncologist. 2026-07-11 - 2 citationsctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer.Ilana B Epstein, Adetolani Odogiyon, Stephanie Berg, Yukako Otani, Charlene Mantia
Clinical Cancer Research. 2026-04-15 - Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617.Margo B Gerke, Angelo Marra, Yuan Liu, Akshay Bedmutha, Jacqueline T Brown
Cancer. 2026-04-15
Press Mentions
Addressing Mental Health in Patients with Lung Cancer Improves OutcomesJuly 30th, 2022- Research Round-up: Lung CancerNovember 18th, 2020
ASCO GU 2020: Adjuvant Options in High-Risk Disease After Primary InterventionFebruary 17th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
